2 hours Ago By Defense World Staff
Unique Wealth LLC grew its position in Eli Lilly and Company ( NYSE:LLY – Free Report ) by 303.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,401 shares of the company’s stock after acquiring an additional 1,054 shares during the period.
Unique Wealth LLC’s holdings in Eli Lilly and Company were worth $1,241,000 as of its most recent filing with the SEC. Several other hedge funds also recently modified their holdings of the company. Capital Planning LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter valued at about $262,000.
CHURCHILL MANAGEMENT Corp acquired a new stake in Eli Lilly and Company during the 1st quarter worth approximately $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $8,896,000. HighPoint Advisor Group LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at approximately $9,878,000.
Finally, Leo Wealth LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $3,355,000. Institutional investors and hedge funds own 82.53% of the company’s stock.
Insider Activity In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.
00. Following the transaction, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20.
The sale was disclosed in a document filed with the SEC, which is available through the SEC website . Corporate insiders own 0.13% of the company’s stock.
Analyst Upgrades and Downgrades View Our Latest Research Report on Eli Lilly and Company Eli Lilly and Company Trading Down 0.7 % LLY opened at $885.15 on Friday.
The company has a fifty day moving average price of $898.50 and a two-hundred day moving average price of $846.49.
Eli Lilly and Company has a 1-year low of $523.63 and a 1-year high of $972.53.
The company has a market cap of $841.25 billion, a P/E ratio of 130.36, a price-to-earnings-growth ratio of 2.
78 and a beta of 0.42. The company has a current ratio of 1.
11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74.
Eli Lilly and Company ( NYSE:LLY – Get Free Report ) last issued its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.
64 by $1.28. Eli Lilly and Company had a return on equity of 67.
52% and a net margin of 18.86%. The business had revenue of $11.
30 billion during the quarter, compared to analyst estimates of $9.83 billion. Analysts predict that Eli Lilly and Company will post 16.
49 EPS for the current fiscal year. Eli Lilly and Company Profile ( Free Report ) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles Five stocks we like better than Eli Lilly and Company Profitably Trade Stocks at 52-Week Highs When Is the Best Time to Invest in Mutual Funds? What is Forex and How Does it Work? Is NVIDIA Stock in a Correction or Consolidation? NYSE Stocks Give Investors a Variety of Quality Options 3 Oversold Stocks with Big RSI Rebound Potential Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter ..
